EICHOR
● Active Not Recruiting
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
Condition: Relapsing-remitting Multiple Sclerosis (RRMS) · Sponsor: Amgen
About this study
The Main objectives of the study are to demonstrate pharmacokinetic (PK) similarity between ABP 692 and ocrelizumab (US), as well as between ABP 692 and ocrelizumab (EU).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (109)
| University of South Alabama | Mobile, Alabama, United States | — |
| Clinical Endpoints, LLC | Scottsdale, Arizona, United States | — |
| Profound Research - Neurology Center of Southern California | Carlsbad, California, United States | — |
| Mountain Neurological Research Center | Basalt, Colorado, United States | — |
| Advanced Neurosciences Research, Llc | Fort Collins, Colorado, United States | — |
| Hasbani Neurology | New Haven, Connecticut, United States | — |
| Neurology Offices of South Florida | Boca Raton, Florida, United States | — |
| Aqualane Clinical Research | Naples, Florida, United States | — |
| Emerald Coast Neurology/Synergy Clinical Research | Pensacola, Florida, United States | — |
| Knight Neurology | Rockledge, Florida, United States | — |
| Premiere Research Institute Palm Beach | West Palm Beach, Florida, United States | — |
| Hawaii Pacific Neuroscience | Honolulu, Hawaii, United States | — |
+ 97 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06700343